DHE is a migraine-specific acute medication first approved in 1946. The FDA's approval of the nasal powder formulation, ...

"DHE plays a unique clinical role in the acute treatment of migraine, providing patients long-lasting effects and the unique ...

Montgomery County is attributing a dramatic decline in drug deaths to efforts to prevent them, including availability of a ...

An antidepressant containing a form of the drug ketamine has been added to the Pharmaceutical Benefits Scheme (PBS), making ...

Kindeva manufactures nasal-based drugs. It celebrated the opening of its new building and recent expansion Thursday.

The FDA has approved Atzumi (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.

Can’t breathe without your nasal spray? You’re not alone. But here’s why that quick fix can cause long-term harm.

The University of Georgia and the state of Georgia are now making naloxone accessible after the significant increase in ...

The US Food and Drug Administration (FDA) has approved Atzumi, a 5.2 mg dihydroergotamine (DHE) nasal powder, for the acute ...

Approval is based on results from the Phase III ASCEND trial, in which patients using the powder achieved freedom from pain ...

The studies showed that the nasal powder had rapid absorption, rapid achievement of high DHE plasma concentrations, and sustained DHE plasma levels. The drug was well tolerated when used long-term ...

Kindeva Drug Delivery, located off of Newtown Pike and Citation Boulevard, specializes in manufacturing life-saving ...